Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Fiebig, Aline A ^a   Zhu, Weijia ^a   Hollerbach, Catherine ^a   Leber, Brian ^a   Andrews, David W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; DOXORUBICIN; ETOPOSIDE; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; THAPSIGARGIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; ENDOPLASMIC RETICULUM; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOCHONDRION; MOLECULAR CLONING; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; WILD TYPE;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; DOXORUBICIN; HUMANS; MUTANT PROTEINS; ORGANELLES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33748668261     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-213     Document Type: Article

References (51)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
2. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
3. Aravind L, Dixit VM, Koorin EV: Apoptotoic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science 2001, 291:1279-1284.
4. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW: X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996, 381:335-341.
5. Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW: Solution structure of the anti-apoptotic protein bcl-2. Proc Nat Acad Sci USA 2001, 98:3012-3017.
6. Evans DE, Mansel RE: Molecular evolution and secondary structure conservation in the B-cell lymphoma leukemia (bcl-2) family of proto-oncogene products. J Mol Evol 1995, 41:775-783.
7. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ: Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995, 182:821-828.
8. Cory S, Adams JM: The Bcl-2 family: regulators of the cellular life-or-death switch. Nature Rev Cancer 2:647-656.
9. Kitada S, Anderson J, Akar S, Zapata JM, Takayama S, Krajewski S, Wan HG, Zhan X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998, 91:3379-3389.
10. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen KJ: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. Pathol 1995, 177:49-55.
11. Gasparini BM, Donglioni C, Palma PL: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node positive breast cancers. Clin Cancer Res 1995, 1:189-198.
12. Olapadu Ol, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB: Overexpression of Bcl-x protein in primary breast cancer is associated with high grade and nodal metastases. Cancer J Sci Am 1997, 3:230-237.
13. Ranger AM, Malynn BA, Korsmeyer SJ: Mouse models of cell death. Nature Gen 2001, 28:113-8.
14. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993, 53:4701-4714.
15. Janiak F, Leber B, Andrews DW: Assembly of Bcl-2 into microsomal and outer mitochondrial membranes. J Biol Chem 1994, 269:9842-9849.
16. Gonzalez-Garcia M, Perez, Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, Nunez G: bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994, 120:3033-3042.
17. Hsu YT, Wolter KG, Youle RG: Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997, 94:3668-3672.
18. Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B, Andrews DW: Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J 1996, 15:4130-4141.
19. Hacki J, Egger L, Monney L, Conous S, Rosse T, Fellay I, Borner C: Apoptotic crosstalk between endoplasmic reticulum and mitochondria controlled by bcl-2. Oncogene 2000, 19:2286-2295.
20. Rudner J, Lepple-Wienhues A, Budach W, Berschauer J, Friedrich B, Wesselborg S, Schulze-Osthoff K, Belka C: Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci 2001, 114-4161-4172.
21. Thomenius MJ, Wang NJ, Reineks EZ, Distelhorst CJ: Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH-3 only proteins. J Biol Chem 2003, 278:6243-6250.
22. Annis MG, Yethon JA, Leber B, Andrews DW: There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. Biochim Biophys Acta 2004, 1644:115-123.
23. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995, 55:3902-3907.
24. Janicke RU, Sprenprt ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360.
25. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin and etoposide-induced apoptosis. Cancer Res 2001, 61:348-354.
26. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965.
27. Feuerhake F, Sigg W, Hofter EA, Dimpfl T, Welsch U: Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland. Cell Tissue Res 299:47-58.
28. Krajewski S, Krajewski M, Shabaik A, Wang HG, Irie S, Fong L, Reed JC: Immunohistochemical analysis of in vivo patterns of Bcl-XL expression. Cancer Res 54:5501-5507.
29. Lee ST, Hoeflich KP, Wasfy GW, Woodgett JR, Lebe B, Andrews DW, Hedley DW, Penn LZ: Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene 1999, 18:3520-8.
30. Annis MG, Zamzami N, Zhu W, Penn LZ, Kroemer G, Leber B, Andrews DW: Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene 2001, 20:1939-52.
31. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG: Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999, 274:28379-84.
32. Gobeil S, Boucher CC, Nadeau D, Poirier GG: Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001, 8:588-94.
33. Hahn SM, Liebmann MD, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D: Taxol in combination with doxorubicin or etoposode: possible antagonism In Vitro. Cancer 1993, 72:2705-11.
34. Denmeade SR, Isaacs JT: The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther 2005, 4:14-22.
35. Ogretmen B, Hannan YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004:604-16.
36. Minotti G, Menna P, Salvatorellai E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
37. Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299-308.
38. Sundararajan R, Cuconati A, Nelson D, White E: Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001, 276:45120-7.
39. Jeong S-Y, Gaume B, Lee Y-J, Hsu Y-T, Ryu S-W, YGon S-H, Youle RJ: Bcl-XL sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers. EMBO J 2004, 19:2146-55.
40. Gottschalk AR, Boise LH, Thompson CB, Quintans J: Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA 1994, 91:7350-4.
41. Johnson DE: Noncaspase proteases in apoptosis. Leukemia 2000, 14:1695-1703.
42. Fadeel B, Hassan Z, Hellstrom-Lindberg E, Henter J-I, Orrenius S, Zhitovsky B: Cleavage of Bcl-2 is an early event inchemotherapy-induced apoptosis of human myeloid leukemia cells. Leukemia 1999, 13:719-28.
43. Cheng EH, Jirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM: Conversion of Bcl-2 to Bax-like death effector by caspases. Science 1997, 278:1966-8.
44. Clem RJ, Cheng EH, Karp CC, Kirsch DG, Kirsch DG, Ueno K, Takahashi A, Kastan MB, Griffen DE, Earnshaw WC, Veliuona MA, Hardwick JM: Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998, 95:554-9.
45. Brown M, Attardi LD: The role of apoptosis in cancer development and treatment response. Nature Rev Cancer 2005, 5:231-237.
46. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DCS: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-XL, but not by Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305.
47. Kim PK, Annis MG, Dlugosz PJ, Leber B, Andrews DW: During apoptosis Bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondria. Mol Cell 2004, 14:523-9.
48. Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado J, Penn LZ, Leber B, Andrews DW: Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005, 24:2096-103.
49. Kaufman T, Schlipf S, Sanz J, Neubert K, Stein R, Borner C: Characterization of the signal that directs Bcl-XL, but not Bcl-2, to the mitochondrial outer membrane. J Cell Biol 2003, 160:53-64.
50. Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP, Chen L, Lackmann M, Lithgow T, Hinds MG, Day CL, Adams JM, Huang DCS: Proapoptototic activity of BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 1993, 162:877-87.
51. Dlugosz P, Billen LP, Annis MG, Zhu W, Zhang Z, Lin J, Leber B, Andrews DW: Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006, 25:2287-96.